Skip to content
Screener

DBV Technologies DBVT Free cash flow

Free cash flow at other companies

Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$14.86M+36.9%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$60.59M-35.4%
Alumis Inc. logo
Alumis Inc.ALMS
-$87.25M-8.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.32M+9.7%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$54.54M+10.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$572.8M-38.1%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
CapEx$400.0K

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Calculated from DBV Technologies’s reported figures.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026. Open the filing →

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453

FAQ

What is DBV Technologies's free cash flow?
DBV Technologies (DBVT) reported free cash flow of -$53M in Q2 2026.
How has DBV Technologies's free cash flow changed year-over-year?
DBV Technologies's free cash flow decreased by 56.3% year-over-year, from -$33.9M to -$53M.
What is the long-term trend for DBV Technologies's free cash flow?
Over 4 years (2021 to 2025), DBV Technologies's free cash flow has grown at a 2.8% compound annual growth rate (CAGR), from -$109.15M to -$121.71M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about DBV Technologies's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude